Abstract
There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms. Incidence of depression is significantly higher among HIV positive individuals compared to HIV negative populations. Also carnitine deficiency is prevalent in HIV positive individuals.
In a cross-sectional study correlation between serum carnitine level and depression severity based on the Beck Depression Inventory questionnaire was assessed in 100 HIV/AIDS (42 males and 58 females) patients. According to the Beck Depression Inventory definitions, 31%, 16%, and 21% of the patients experienced mild, moderate, and severe depression, respectively.
The mean ± SD serum concentration of total carnitine in the patients was 37.96 ± 26.08 (µmol/L). Fifty-four (54%) patients were categorized as carnitine deficient. A non-statistically significant negative correlation between patients’ depression scores and total levels of serum carnitine was found. Considering the prevalence of depression among HIV/AIDS patients and probable role of carnitine in the pathogenesis of depressive disorders, more studies are needed to reveal correlation between depression and the body storage of carnitine.
Keywords: Depression, carnitine, HIV/AIDS.
Current HIV Research
Title:Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients
Volume: 11 Issue: 3
Author(s): Haleh Rezaee, Hossein Khalili, Shima Hatamkhani, Simin Dashti-Khavidaki and Zahra Khazaeipour
Affiliation:
Keywords: Depression, carnitine, HIV/AIDS.
Abstract: There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms. Incidence of depression is significantly higher among HIV positive individuals compared to HIV negative populations. Also carnitine deficiency is prevalent in HIV positive individuals.
In a cross-sectional study correlation between serum carnitine level and depression severity based on the Beck Depression Inventory questionnaire was assessed in 100 HIV/AIDS (42 males and 58 females) patients. According to the Beck Depression Inventory definitions, 31%, 16%, and 21% of the patients experienced mild, moderate, and severe depression, respectively.
The mean ± SD serum concentration of total carnitine in the patients was 37.96 ± 26.08 (µmol/L). Fifty-four (54%) patients were categorized as carnitine deficient. A non-statistically significant negative correlation between patients’ depression scores and total levels of serum carnitine was found. Considering the prevalence of depression among HIV/AIDS patients and probable role of carnitine in the pathogenesis of depressive disorders, more studies are needed to reveal correlation between depression and the body storage of carnitine.
Export Options
About this article
Cite this article as:
Rezaee Haleh, Khalili Hossein, Hatamkhani Shima, Dashti-Khavidaki Simin and Khazaeipour Zahra, Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients, Current HIV Research 2013; 11 (3) . https://dx.doi.org/10.2174/1570162X11311030007
DOI https://dx.doi.org/10.2174/1570162X11311030007 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Xenogeneic Decellularized Extracellular Matrix-based Biomaterials For Peripheral Nerve Repair and Regeneration
Current Neuropharmacology Cell Adhesion Molecules in Gene and Cell Therapy Approaches for Nervous System Repair
Current Gene Therapy Mesothelioma - Update on Management
Current Respiratory Medicine Reviews A Systematic Review of Mesenchymal Stem Cells in Spinal Cord Injury, Intervertebral Disc Repair and Spinal Fusion
Current Stem Cell Research & Therapy L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Realising Heart Regeneration
Current Tissue Engineering (Discontinued) Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Neural Induction and Patterning in Mammalian Pluripotent Stem Cells
CNS & Neurological Disorders - Drug Targets Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice
CNS & Neurological Disorders - Drug Targets Therapeutic Antibodies for Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets MicroRNAs: Newcomers into the ALS Picture
CNS & Neurological Disorders - Drug Targets COVID-19 and Neurology: An Emerging Association
Infectious Disorders - Drug Targets Role of PGE2 in Blood Pressure Regulation
Current Hypertension Reviews Editorial: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part II)
Current Molecular Pharmacology